Cytomegalovirus infects 60–90% of adults by age 70 and silently consumes up to 30% of the body's T-cell reserve. Epstein-Barr virus has now been linked to multiple sclerosis. Both are targets of an emerging mRNA vaccine pipeline that could extend the logic of the shingles vaccine to the next frontier of longevity medicine.
The shingles vaccine's association with slower biological aging introduced a paradigm that longevity medicine has been slow to fully absorb: latent viruses are not passive passengers. They reactivate, generate chronic immune activation, and accelerate aging through a mechanism called inflammaging. Varicella-zoster virus (VZV) is the one for which we now have population-level biological aging data and a highly effective vaccine.
But VZV is not the only herpesvirus hiding in your body. Two others — cytomegalovirus (CMV) and Epstein-Barr virus (EBV) — are arguably more consequential for immune aging and are now at the center of one of the most promising developments in longevity-adjacent medicine: mRNA vaccine programs targeting latent viral burden.
This article covers what CMV and EBV do to the aging immune system, why their effects go well beyond the infections they cause, and what the current vaccine pipeline looks like for both.
To understand why CMV and EBV matter for aging, you need the basic biology of herpesvirus latency.
Herpesviruses — a family that includes VZV (shingles), CMV, EBV, herpes simplex viruses (HSV-1 and HSV-2), and several others — share one defining characteristic: after primary infection, they are never fully cleared. The immune system suppresses replication, but the virus retreats into specific cell populations and establishes a permanent latent state.
For CMV, the primary reservoir is monocytes and their precursors in bone marrow. For EBV, it is long-lived memory B cells. Once established, these reservoirs persist for life.
This permanence would be manageable if the immune system maintained perfect surveillance forever. The problem is that it doesn't. As the immune system ages — a process called immunosenescence — the capacity to hold latent viruses in check declines. The viruses respond by reactivating more frequently, generating bursts of viral antigen production, triggering immune responses, and then retreating back to latency. Each reactivation cycle adds to the body's cumulative inflammatory burden.
This is the latent viral burden hypothesis for aging: the lifelong effort to manage these hidden infections steadily consumes immune resources, drives chronic inflammation, and contributes to the progressive deterioration of immune competence that characterizes aging.
Cytomegalovirus is the most extensively studied latent virus in the context of immune aging, and the data are striking.
CMV seroprevalence — the proportion of people with evidence of past infection — increases dramatically with age:
| Age Group | Approximate Seroprevalence |
| Adults 20–29 | ~40–50% |
| Adults 40–49 | ~55–65% |
| Adults 60–69 | ~70–80% |
| Adults 70+ | ~80–90% |
By the eighth decade of life, the vast majority of people carry CMV. In lower-income countries and among people who grew up in crowded conditions, seroprevalence is higher still — often 90–100% by early adulthood.
CMV is transmitted through saliva, urine, breast milk, blood, and sexual contact. Most primary infections in immunocompetent adults are asymptomatic or produce a mild mononucleosis-like illness. The primary infection passes, and the virus enters latency. Most people never know they have it.
What happens next is what matters for aging. The immune system devotes substantial ongoing resources to CMV surveillance. In younger, CMV-positive adults, this is manageable. In older adults, it becomes a significant problem.
The phenomenon is called immune inflation — and it is one of the most dramatic and well-characterized consequences of CMV carriage in aging.
Under normal circumstances, antigen-specific T cells expand when their target antigen appears and then contract when the antigen is cleared. The immune system's memory is maintained by a small pool of long-lived memory T cells, with the effector population shrinking once the threat resolves.
CMV disrupts this economy. Because CMV reactivates periodically rather than being fully cleared, the immune system never fully resolves the "threat." Antigen-specific CD8+ T cells — the cytotoxic T cells that kill virus-infected cells — continue to expand with each reactivation cycle. In CMV-seropositive individuals over 65, CMV-specific T cells can account for 10–30% of the entire circulating CD8+ T cell pool.
To put that in perspective: in a typical older adult, one in ten to one in three of all T cells capable of killing infected cells may be devoted to monitoring a single pathogen. These are T cells that cannot be easily redirected to fight new threats — influenza, COVID-19, cancers, other infections. This is the immune exhaustion and "memory inflation" that CMV drives.
Researchers studying why elderly individuals respond poorly to new vaccines — including influenza, pneumococcal, and COVID-19 vaccines — have consistently found CMV seropositivity as a significant adverse factor. The mechanism is precisely this immune inflation: the T cell repertoire has been narrowed by CMV-specific clonal expansion, leaving less flexibility for new immune responses.
The relationship between CMV and immune aging has been formalized in the concept of the Immune Risk Profile (IRP), first described by Anders Wikby and colleagues in Swedish longevity studies in the 1990s and 2000s.
The IRP is a cluster of immune markers that predicts mortality in elderly populations better than many conventional clinical measures. It includes:
CMV seropositivity is the strongest single predictor within the IRP. In the Swedish OCTO and NONA longitudinal studies, elderly individuals with the complete Immune Risk Profile had significantly higher two-year and four-year mortality, independent of conventional risk factors.
More recent analyses have confirmed this signal across different populations. A 2022 analysis using UK Biobank data found that CMV seropositivity in adults aged 40–70 was associated with accelerated biological aging by epigenetic clock measures, with the association strengthening in older age groups.
CMV's impact is not limited to immune aging. Several lines of evidence link CMV to cardiovascular disease:
The cardiovascular connection is not as cleanly established as the immune aging connection, and causation versus correlation remains an active research question. But the biological plausibility is high: a virus that chronically drives inflammatory cytokine production and infects the vascular endothelium has multiple potential routes to cardiovascular damage.
A less-discussed but potentially important consequence of CMV-driven immune inflation is its effect on cancer immunosurveillance.
The immune system's ability to recognize and eliminate nascent cancer cells depends on maintaining a diverse, responsive T cell repertoire. When a substantial fraction of that repertoire is locked into CMV surveillance, the capacity for cancer immunosurveillance is theoretically reduced.
Direct evidence for this effect in human populations is difficult to establish because of confounding — older people have both higher CMV seroprevalence and higher cancer rates, for obvious age-related reasons. But in mouse models and in the context of solid organ transplantation (where CMV reactivation is common and immunosuppression is ongoing), the interaction between CMV, immune exhaustion, and malignancy risk is well established.
The case for a CMV vaccine predates the mRNA era. CMV is the most common infectious cause of birth defects in the United States — primary CMV infection during pregnancy can cause hearing loss, neurological damage, and developmental delay in newborns. The Institute of Medicine identified CMV vaccine development as a national priority in 2000.
What changed with mRNA technology is the feasibility of targeting CMV's complex surface proteins with the precision and speed that prior vaccine platforms struggled to achieve.
CMV has a large, complex genome — roughly five times the size of influenza's — encoding more than 200 proteins. Its surface presents multiple potential vaccine targets, but the most important are:
Early CMV vaccine candidates focused almost exclusively on gB. While gB-based vaccines generated immune responses, they provided only modest protection (approximately 50% efficacy in trials of the MF59-adjuvanted gB vaccine). The pentameric complex was identified later as a key target for neutralizing antibodies against epithelial cell entry, but producing the PC in a form that reliably induces strong immune responses proved difficult with protein-based platforms.
Moderna's mRNA-1647 represents the most advanced current effort to develop a CMV vaccine. The vaccine encodes six CMV protein antigens via mRNA:
By encoding all six antigens in a single mRNA vaccine, Moderna enables the immune system to generate responses against both the gB and PC targets simultaneously — something that had been difficult to achieve with earlier platforms.
Phase 2 data (published 2022, *New England Journal of Medicine*): A Phase 2 trial in 180 CMV-seronegative women of childbearing age found that mRNA-1647 produced significantly higher titers of neutralizing antibodies against CMV infection of epithelial cells — the entry route most relevant to congenital infection — compared to the earlier gB/MF59 vaccine. The pentameric complex antigens were driving a meaningfully stronger response against the most clinically relevant mode of CMV entry.
Phase 3 trial (CMVictory, ongoing): Moderna initiated the Phase 3 CMVictory trial to evaluate mRNA-1647 in women of childbearing age, the population for whom CMV infection during pregnancy poses the greatest risk of birth defects. The trial is designed to assess protection against primary CMV infection. As of 2025, CMVictory is ongoing, with results expected in the 2026–2027 timeframe.
The primary development rationale for mRNA-1647 is congenital CMV prevention — preventing birth defects, not extending lifespan. But from a longevity medicine perspective, the more interesting question is what a CMV vaccine might do for adults who are already seropositive.
This is a fundamentally different challenge. Preventing primary CMV infection in a seronegative individual is conceptually straightforward. Reducing viral burden and reactivation frequency in someone who has carried CMV for decades — potentially with established immune inflation and T-cell exhaustion — is a different problem entirely.
Therapeutic vaccination — vaccinating people who are already infected to modulate the viral-immune balance rather than prevent infection — has been explored in other viral contexts (HIV, hepatitis B, herpes simplex), with modest results to date. Whether a therapeutic CMV vaccine could reduce reactivation frequency, shrink the CMV-specific T cell pool, or restore immune repertoire diversity in elderly seropositive individuals is an open and important research question.
The mechanism by which the shingles vaccine slows biological aging is hypothesized to involve exactly this: suppressing VZV reactivation reduces chronic viral antigen exposure and the associated inflammaging. If a CMV vaccine could achieve the same effect against a virus that drives immune inflation on a far larger scale, the potential longevity benefit could be substantial.
No Phase 3 trial currently tests a CMV vaccine specifically for biological aging or immune rejuvenation outcomes in elderly seropositive adults. This is the gap in the research that the field needs to fill.
Epstein-Barr virus has a different and in some ways even more surprising story.
EBV seroprevalence rivals CMV: by adulthood, approximately 90–95% of the global population has been infected. Primary EBV infection typically occurs in childhood, where it is often asymptomatic or produces mild illness. When primary infection is delayed to adolescence or young adulthood — as commonly happens in high-income countries — it causes infectious mononucleosis: the classic "mono" with fever, extreme fatigue, lymph node swelling, and sore throat that can last weeks.
After primary infection, EBV establishes latency in long-lived memory B cells, where it persists for life. Unlike CMV, EBV does not typically drive the same magnitude of T cell immune inflation in most seropositive individuals. But it has two other properties that make it uniquely consequential.
In January 2022, *Science* published a landmark study from Bjornevik et al. that, for practical purposes, established EBV as a necessary cause of multiple sclerosis (MS).
The study leveraged a unique dataset: serum samples collected from 10 million US military personnel over 20 years, with stored biospecimens allowing researchers to look back at what had happened immunologically *before* MS diagnosis. This longitudinal design — with pre-disease samples — is extremely rare and allowed a causal inference that case-control or cross-sectional studies cannot provide.
Key findings:
The near-complete absence of EBV-seronegative MS cases — in a dataset of 801 patients — is statistically extraordinary. EBV is not merely associated with MS. EBV appears to be necessary for MS, even if not sufficient (most EBV-infected individuals do not develop MS, suggesting other genetic and environmental factors determine who among the infected minority progresses to disease).
Subsequent work has proposed a molecular mimicry mechanism: EBV encodes a protein (EBNA1) that shares structural similarity with a myelin protein (GlialCAM). Antibodies generated against EBNA1 — part of the normal immune response to EBV — may cross-react with GlialCAM expressed in the central nervous system, triggering the autoimmune attack on myelin that characterizes MS.
This mechanism has now been replicated across multiple laboratories. A 2022 *Nature* paper from Lanz et al. found anti-EBNA1 antibodies that cross-reacted with GlialCAM in a substantial fraction of MS patients, and showed that these cross-reactive antibodies could cause neural damage in animal models.
If confirmed, this places EBV at the center of one of the most debilitating and poorly understood autoimmune diseases — and makes EBV vaccination a potential MS prevention strategy.
MS is not the only autoimmune condition linked to EBV. A growing body of epidemiological and mechanistic evidence implicates EBV in:
The full scope of EBV's contribution to autoimmune disease burden is not yet clear. What is increasingly clear is that the virus's ability to chronically perturb B cell biology and antibody production — through its permanent residence in memory B cells — creates ongoing potential for molecular mimicry and autoreactivity.
EBV's contribution to immune aging is distinct from CMV's but not trivial. The virus drives a chronic, low-level activation of EBV-specific T cells — not at the scale of CMV's immune inflation, but measurably present in older EBV-seropositive individuals.
More importantly, EBV reactivation frequency increases with age and immunosenescence. Reactivation in EBV-seropositive older adults generates bursts of latent membrane proteins and viral antigens that trigger immune responses and contribute to background inflammatory load.
Several studies have found that EBV reactivation — measured by elevated EBV-specific antibody titers or detectable EBV DNA in blood — is associated with:
This is the same inflammaging mechanism that operates with CMV and VZV. The three herpesviruses differ in the scale and character of their immune effects, but share the fundamental logic: chronic latency + immunosenescent reactivation = cumulative inflammatory burden.
The same mRNA platform that produced the COVID-19 vaccines — and that Moderna is applying to CMV — has generated early-stage EBV vaccine programs. These are less advanced than mRNA-1647 but represent a genuinely new development in a field that had seen limited vaccine progress for decades.
Moderna has disclosed development of mRNA-1189, targeting EBV surface glycoproteins including gp350 (the major envelope glycoprotein and the primary target of neutralizing antibodies) and the pentameric complex relevant to B cell entry.
As of 2025, mRNA-1189 is in early clinical development. Phase 1 data have not yet been publicly released in full.
The primary target population for mRNA-1189 in current development is adolescents and young adults — the population at highest risk for symptomatic infectious mononucleosis on primary EBV infection and, crucially, the population for whom preventing EBV infection could substantially reduce MS risk, given that EBV infection must precede MS development by years to decades.
Perhaps the most ambitious near-term development is Moderna's mRNA-1116, a combination vaccine targeting both CMV and EBV simultaneously. This is conceptually aligned with the mRNA platform's advantage: the ability to encode multiple antigens in a single shot, delivering protection against several targets in one administration.
Combination delivery would be particularly valuable from a public health and compliance standpoint — a single adolescent vaccine that prevents both congenital CMV and MS-triggering EBV infection would be extraordinarily impactful if it works.
Clinical program details for mRNA-1116 are limited as of early 2026; Moderna has confirmed the program's existence but has not disclosed Phase 1 enrollment timelines.
Beyond Moderna, several other organizations are working on EBV vaccines:
None of these non-mRNA candidates are as advanced or as closely watched as Moderna's mRNA programs from a longevity medicine perspective.
| Feature | VZV (Shingles) | CMV | EBV |
| Seroprevalence (adults 60+) | ~95–99% | ~70–90% | ~95%+ |
| Primary immune aging mechanism | Reactivation → inflammation | Immune inflation, T-cell exhaustion | Reactivation, molecular mimicry |
| Scale of T-cell impact | Moderate | Severe (10–30% of CD8 pool) | Mild–moderate |
| Key disease links | Shingles, PHN, stroke | Poor vaccine response, mortality | MS, multiple autoimmune diseases |
| Biological aging data | Strong (Kim & Crimmins 2025) | Emerging (UK Biobank, OCTO/NONA) | Preliminary |
| Vaccine available | Yes — Shingrix (97% efficacy) | No — Phase 3 ongoing (mRNA-1647) | No — Phase 1 (mRNA-1189) |
| Therapeutic vaccine potential | Not studied | Theoretical, unproven | Speculative |
The practical implications of the CMV and EBV research depend on where we are in the evidence cycle.
What is established:
What is not yet established:
What this means for current protocol-building:
The clearest current action is the one the shingles vaccine article already covers: if you are 50 or older, Shingrix is the intervention with the strongest available evidence that directly targets latent viral burden as an aging accelerant. Get it if you haven't.
For CMV and EBV, the interventions don't yet exist in approved form. The relevant question for anyone tracking this space is whether to participate in trials when they become available, and how to track the ongoing Phase 3 CMVictory results.
For those interested in understanding their own CMV and EBV status, testing is available but of limited clinical utility at present:
CMV serology: A standard CMV IgG antibody test establishes whether you have been infected. This is widely available. A positive result tells you that you carry CMV and that your immune system is devoting resources to managing it. Beyond identifying seropositivity, current clinical testing cannot tell you the reactivation frequency, the degree of immune inflation, or whether your immune system's CMV burden is typical or unusually high for your age.
T-cell immunophenotyping: Research laboratories can measure the proportion of CMV-specific T cells, the CD4:CD8 ratio, and markers of T cell exhaustion and late differentiation. These are the measures used in the Immune Risk Profile studies. They are not part of standard clinical care, but they are available through specialized longevity clinics and academic medical centers as out-of-pocket tests.
EBV serology: EBV VCA IgG and EBNA IgG antibodies establish past infection. Elevated VCA IgA or EA (early antigen) antibodies suggest more recent or ongoing reactivation — a pattern associated with elevated MS risk in some research contexts. Routine clinical monitoring for EBV reactivation is not standard outside of immunocompromised patients.
The CMV, EBV, and VZV research converges on a single conceptual point that deserves to be central to how longevity medicine approaches aging biology.
Aging is not only an intrinsic cellular program. It is also shaped by the cumulative extrinsic burdens that the body has accumulated over a lifetime — and among those burdens, latent viral infections are among the most consequential and most modifiable.
The immune system's lifelong effort to manage herpesviruses that established permanent latency in childhood or young adulthood generates decades of chronic immune activation, drives the exhaustion of immune cell populations, contributes to systemic inflammation, and narrows the immune repertoire's capacity to respond to new challenges.
Vaccines that prevent primary infection eliminate the burden entirely for future cohorts. Therapeutic vaccines that reduce reactivation in already-infected individuals — if they can be developed — would represent a new class of longevity intervention for the current generation of older adults.
This is not science fiction. The shingles vaccine data demonstrates that suppressing a latent herpesvirus produces measurable, multi-system improvements in biological aging. The question is not whether the mechanism is real — the VZV data establish that it is. The question is whether the same logic, applied to CMV and EBV with the tools the mRNA platform is now making feasible, will yield comparable results.
The answer will come from the trials currently underway. For a field that has spent decades focused on cellular senescence, NAD+ metabolism, mTOR signaling, and other intrinsic aging pathways, the latent viral burden story represents a genuinely orthogonal and underexplored target — one where approved interventions (for VZV) already exist, where the biological mechanism is well-characterized, and where the next generation of tools (mRNA CMV and EBV vaccines) is closer than most longevity-focused individuals realize.
If you are 50 or older: The priority action is Shingrix if you haven't had it. This is the intervention in this paradigm with the strongest evidence and immediate availability. See the companion shingles vaccine article for full coverage.
If you are interested in CMV vaccine trials: The CMVictory Phase 3 trial for mRNA-1647 is focused on prevention of primary CMV infection in women of childbearing age. A longevity-focused trial in elderly seropositive individuals does not currently exist. ClinicalTrials.gov is the appropriate resource for monitoring any emerging therapeutic CMV vaccine programs.
If you have MS or are in a high-risk family for MS: The EBV-MS causal link has been established at the population level. Whether vaccination of EBV-seronegative adolescents could prevent MS is a genuine possibility — but trials testing this hypothesis would require following large populations for decades given MS's long latency. Watch for NIH and Moderna EBV vaccine Phase 2/3 announcements.
If you are building a general longevity protocol: The latent virus story reinforces the value of anti-inflammatory interventions broadly, and specifically argues for vaccination as a high-leverage point. The evidence hierarchy currently places Shingrix at the top, with CMV and EBV vaccines to follow as they progress through trials.
The latent viral burden hypothesis for aging is compelling and increasingly well-supported, but it carries genuine uncertainties worth naming:
Correlation vs. causation in aging studies: The CMV-immune aging associations are observational. It is possible that individuals who age faster for other reasons also show worse CMV control, rather than CMV causing accelerated aging. Intervention trials with CMV vaccines would clarify this.
The therapeutic vaccination challenge: Modifying the immune relationship with a virus you have carried for 40 years is qualitatively different from preventing new infection. Therapeutic vaccines for HIV and herpes simplex have had limited success. CMV and EBV therapeutic vaccination is speculative until clinical data exist.
Individual variation: CMV seropositivity does not affect all older adults equally. Some CMV-seropositive individuals show minimal immune inflation; others show dramatic narrowing of the T cell repertoire. The factors driving this individual variation — viral strain, age of infection, genetic immune factors — are not fully characterized.
MS causation vs. EBV prevention: Even if EBV is necessary for MS, EBV vaccination in adolescents would need to achieve sufficient efficacy against infection to meaningfully reduce population-level MS incidence. MS incidence would also be the outcome measure requiring decades of follow-up to assess reliably.